• Lifeward posted Q1 net loss of $10.8 million, or $6.70 per share, widening from year-ago levels, as revenue fell 22% to $3.9 million.
• Operating loss widened to $10.3 million, driven by a one-time, non-cash R&D charge of about $4.9 million tied to acquired in-process R&D from the Oratech transaction.
• Gross margin slipped 8 percentage points to 34.2% on lower production volumes, higher tariffs, and foreign-exchange swings.
• Cash used in operating activities dropped 33% year over year to $3.7 million, while unrestricted cash and equivalents rose to $11.4 million following convertible notes proceeds and $6.5 million of cash acquired in the Oratech deal.
• Strategic transaction closed with equity-based acquisition of Oratech alongside $10 million financing; ReWalk personal exoskeleton sales rose 11% to $1.6 million as reimbursement coverage expanded at Aetna, Humana, and UnitedHealthcare.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-002727), on May 15, 2026, and is solely responsible for the information contained therein.